SCHEMBL2117903

SCHEMBL2117903

CC(C)(C)OC(=O)N1CC[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1[C@H](CNC(=O)OCc1ccccc1)c1c[nH]c2cc(F)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 2/20 0.41
ABCB1 P08183 1/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAPT P10636 2/20 0.37
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
BACE1 P56817 2/20 0.35
P2RX7 Q99572 1/20 0.35
BACE2 Q9Y5Z0 1/20 0.35
SYK P43405 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
RORC P51449 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TP53 P04637 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KLK7 P49862 1/20 0.33
MAPK1 P28482 1/20 0.33
NTSR1 P30989 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2439337 0.92 ABCB1 (0.40) ABCB1SYKMEN1KMT2AKLK7
SCHEMBL2442155 0.91 TGM2 (0.41) TGM2ABCB1LMNASMN1; SMN2MAPT
SCHEMBL2442154 0.91 TGM2 (0.41) TGM2ABCB1LMNASMN1; SMN2MAPT
SCHEMBL2436780 0.91 TGM2 (0.41) TGM2ABCB1LMNASMN1; SMN2MAPT
SCHEMBL12299669 0.91 TGM2 (0.41) TGM2ABCB1LMNASMN1; SMN2MAPT
SCHEMBL12299704 0.91 TGM2 (0.41) TGM2ABCB1LMNASMN1; SMN2MAPT
SCHEMBL2115303 0.89 TGM2 (0.41) TGM2ABCB1LMNASMN1; SMN2MAPT
SCHEMBL2114665 0.89 TGM2 (0.39) TGM2ABCB1LMNASMN1; SMN2MAPT
SCHEMBL2443386 0.87 TGM2 (0.38) TGM2ABCB1LMNASMN1; SMN2MAPT
SCHEMBL12299698 0.87 TGM2 (0.38) TGM2ABCB1LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2434889-B1 IAP INHIBITORS TETRALOGIC BIRINAPANT UK LTD (GB) 2016-03-09 EP disclosed
US-20130274278-A1 IAP INHIBITORS TETRALOGIC PHARM CORP (US) 2013-10-17 US disclosed
US-20130274278-A1 IAP INHIBITORS TETRALOGIC PHARM CORP (US) 2013-10-17 US disclosed
US-20130274278-A1 IAP INHIBITORS TETRALOGIC PHARM CORP (US) 2013-10-17 US disclosed
US-8481495-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2013-07-09 US disclosed
US-8481495-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2013-07-09 US disclosed
US-8481495-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2013-07-09 US disclosed
US-8415486-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-04-09 US disclosed
US-8415486-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-04-09 US disclosed
US-8415486-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-04-09 US disclosed
US-8399683-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS (US) 2013-03-19 US disclosed
US-8399683-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS (US) 2013-03-19 US disclosed
US-20120135990-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. (US) 2012-05-31 US disclosed
US-20120135990-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. (US) 2012-05-31 US disclosed
US-20120094917-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP (US) 2012-04-19 US disclosed
US-20120094917-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP (US) 2012-04-19 US disclosed
US-20110237517-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. 2011-09-29 US disclosed
US-20110237517-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237517-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 TGM2 2702/4885ABCB1 393/4885LMNA 767/4885
US-20120135990-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 TGM2 2702/4885ABCB1 393/4885LMNA 767/4885
US-20130274278-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 TGM2 2702/4885ABCB1 393/4885LMNA 767/4885
US-20120094917-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 TGM2 2702/4885ABCB1 393/4885LMNA 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.